Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 70.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,276 shares of the biotechnology company's stock after acquiring an additional 2,999 shares during the period. SG Americas Securities LLC's holdings in Blueprint Medicines were worth $644,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Headlands Technologies LLC acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $65,000. Thematics Asset Management acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $72,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 62.7% during the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 375 shares in the last quarter. Asset Management One Co. Ltd. acquired a new position in shares of Blueprint Medicines during the fourth quarter worth $88,000. Finally, Van ECK Associates Corp grew its stake in shares of Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares in the last quarter.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several research analyst reports. Morgan Stanley upped their price objective on shares of Blueprint Medicines from $102.00 to $129.00 and gave the company an "equal weight" rating in a research note on Thursday, June 5th. HC Wainwright restated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, May 2nd. Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a "buy" rating and a $135.00 price objective for the company. UBS Group upped their price objective on shares of Blueprint Medicines from $88.00 to $129.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Finally, Wells Fargo & Company downgraded shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating and decreased their price objective for the company from $143.00 to $129.00 in a research note on Tuesday, June 17th. Eighteen equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of "Hold" and an average price target of $128.06.

Insiders Place Their Bets

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 5,000 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total transaction of $505,700.00. Following the transaction, the director now directly owns 146,630 shares in the company, valued at approximately $14,830,158.20. This represents a 3.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. This represents a 3.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,574 shares of company stock worth $1,465,528. 4.21% of the stock is owned by company insiders.

Blueprint Medicines Stock Performance

NASDAQ BPMC traded up $0.08 during trading hours on Friday, hitting $128.20. 4,506,150 shares of the stock were exchanged, compared to its average volume of 1,257,773. The company has a market cap of $8.28 billion, a price-to-earnings ratio of -51.90 and a beta of 0.84. Blueprint Medicines Corporation has a 12-month low of $73.04 and a 12-month high of $128.34. The stock has a 50-day moving average of $104.75 and a 200 day moving average of $98.16. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 1.01.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 64.60% and a negative net margin of 27.70%. The firm had revenue of $149.41 million for the quarter, compared to analysts' expectations of $158.31 million. During the same period in the prior year, the company earned $1.40 earnings per share. The company's revenue for the quarter was up 55.5% on a year-over-year basis. As a group, equities research analysts forecast that Blueprint Medicines Corporation will post -1.28 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.